Research programme: CRISPR gene-edited CAR-T cell therapeutics - ToolGen

Drug Profile

Research programme: CRISPR gene-edited CAR-T cell therapeutics - ToolGen

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ToolGen
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Jul 2018 ToolGen has patent protection in South Korea and Australia
  • 31 Jul 2018 ToolGen receives a notice of decision from EPO to grant patent for CRISPR/Cas9 genome editing system in European countries including Austria, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, and United Kingdom
  • 18 May 2018 Preclinical trials in Cancer in South Korea (Parenteral) before 18 May 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top